Cardima To Host Breakfast Scientific Symposium at NASPE Friday, May 10, 2002; Symposium To Showcase REVELATION Series for Treatment of AF.

Business Editors & Health/Medical Writers

FREMONT, Calif.--(BW HealthWire)--May 8, 2002

Cardima(R), Inc. (Nasdaq:CRDM) -- developer of the REVELATION(TM) Tx and REVELATION(TM) Helix(TM) microcatheter systems -- will host a breakfast symposium showcasing the results of the most recent developments in atrial fibrillation (AF) treatment using the REVELATION family of microcatheters at the 23rd Annual Scientific Session of the North American Society for Pacing and Electrophysiology (NASPE) to be held in San Diego, California, from May 7th through 11th, 2002. A total of 6,500 physicians, related medical professionals and industry representatives are expected to attend the NASPE conference this year.

Cardima's breakfast symposium, "Advances in RF Linear Ablation," will be held on May 10th, 2002. The symposium panel will be chaired by Warren M. Jackman, M.D., Professor of Medicine and Director of Clinical Electrophysiology, University of Oklahoma, and will feature recognized speakers from prestigious centers for electrophysiology, including Dr. Abraham Kocheril, Head, Cardiac Electrophysiology, Associate Professor of Medicine of the University of Illinois; Dr. Sung Chun, Associate Director, Cardiac Electrophysiology & Arrhythmia Service of Stanford University; Priv. Doz. Dr. med. Thorsten Lewalter, Medizinische Klinik und Poliklinik II University of Bonn, Germany; Dr. Vivek Reddy, Co-Director, Experimental Electrophysiology Laboratory Cardiac Arrhythmia Service of Massachusetts General Hospital; and Dr. Douglas Packer of the Mayo Foundation, Minnesota.

"We are expecting another standing-room only event as this prominent panel presents clinical data on both the REVELATION Tx and REVELATION Helix," stated Gabriel Vegh, Chief Executive Officer of Cardima. "We are extremely pleased with the early information coming from our European trial with the REVELATION Helix and this will be the first opportunity to publicly present our initial results."

Cardima, Inc. has completed the necessary patient enrollment in Phase III clinical trials in the U.S. with the REVELATION Tx as of December 2001. In order to submit the fifth and final module to our PMA application, we must follow these patients for six months, which is expected to be complete in June 2002, prepare the results of the study and then submit the data to the FDA. We expect to submit this data in August 2002 to the FDA and seek an expedited review at that time. Cardima has also developed the circumferential ablation REVELATION Helix microcatheter system, which received CE mark approval in Europe in December 2001, for the treatment of AF originating in the pulmonary veins.

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include the Company's ability to raise additional capital, conduct successful clinical trials, obtain regulatory approvals and gain acceptance from the marketplace for its products. Additional risks are set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2001, Quarterly Reports on Form 10-Q and other reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.